Sartorius Stedim Biotech S.A. Statistics
Share Statistics
Sartorius Stedim Biotech S.A. has 97.3M
shares outstanding. The number of shares has increased by -0.02%
in one year.
| Shares Outstanding | 97.3M |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | -0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 28.63K, so 0% of the outstanding
shares have been sold short.
| Short Interest | 28.63K |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 923.58 |
Valuation Ratios
The PE ratio is 104.08 and the forward
PE ratio is 36.97.
Sartorius Stedim Biotech S.A.'s PEG ratio is
-2.26.
| PE Ratio | 104.08 |
| Forward PE | 36.97 |
| PS Ratio | 6.56 |
| Forward PS | 4.2 |
| PB Ratio | 4.57 |
| P/FCF Ratio | 38.34 |
| PEG Ratio | -2.26 |
Financial Ratio HistoryEnterprise Valuation
Sartorius Stedim Biotech S.A. has an Enterprise Value (EV) of 20.41B.
| EV / Sales | 7.34 |
| EV / EBITDA | 30.45 |
| EV / EBIT | 25.05 |
| EV / FCF | 42.95 |
Financial Position
The company has a current ratio of 1.85,
with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.85 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 4.28 |
| Debt / FCF | 6.04 |
| Interest Coverage | 2.48 |
Financial Efficiency
Return on Equity is 4.39% and Return on Invested Capital is 4.09%.
| Return on Equity | 4.39% |
| Return on Assets | 2.12% |
| Return on Invested Capital | 4.09% |
| Revenue Per Employee | $279,088.44 |
| Profits Per Employee | $17,578.56 |
| Employee Count | 9,961 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 2.3 |
Taxes
| Income Tax | 40.7M |
| Effective Tax Rate | 18.57% |
Stock Price Statistics
The stock price has increased by 6.34% in the
last 52 weeks. The beta is 0.95, so Sartorius Stedim Biotech S.A.'s
price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | 6.34% |
| 50-Day Moving Average | 215.45 |
| 200-Day Moving Average | 204.71 |
| Relative Strength Index (RSI) | 47.78 |
| Average Volume (20 Days) | 1,212 |
Income Statement
In the last 12 months, Sartorius Stedim Biotech S.A. had revenue of 2.78B
and earned 175.1M
in profits. Earnings per share was 1.81.
| Revenue | 2.78B |
| Gross Profit | 1.21B |
| Operating Income | 370.6M |
| Net Income | 175.1M |
| EBITDA | 670.5M |
| EBIT | 368.8M |
| Earnings Per Share (EPS) | 1.81 |
Full Income StatementBalance Sheet
The company has 678.9M in cash and 2.87B in
debt, giving a net cash position of -2.19B.
| Cash & Cash Equivalents | 678.9M |
| Total Debt | 2.87B |
| Net Cash | -2.19B |
| Retained Earnings | 2.54B |
| Total Assets | 8.3B |
| Working Capital | 815.3M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 815.1M
and capital expenditures -339.8M, giving a free cash flow of 475.3M.
| Operating Cash Flow | 815.1M |
| Capital Expenditures | -339.8M |
| Free Cash Flow | 475.3M |
| FCF Per Share | 4.91 |
Full Cash Flow StatementMargins
Gross margin is 43.41%, with operating and profit margins of 13.33% and 6.3%.
| Gross Margin | 43.41% |
| Operating Margin | 13.33% |
| Pretax Margin | 7.88% |
| Profit Margin | 6.3% |
| EBITDA Margin | 24.12% |
| EBIT Margin | 13.33% |
| FCF Margin | 17.1% |
